Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Durvalumab + MEDI0457|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 89||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|MEDI0457||INO-3112|INO3112|INO 3112|MEDI 0457|MEDI-0457||MEDI0457 (INO-3112) is an immunotherapy consisting of DNA plasmids encoding HPV oncoproteins, E6 and E7, along with interleukin-12 (IL-12) (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5525-5525, PMID: 32151670).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03162224||Phase Ib/II||Durvalumab + MEDI0457||Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer||Completed||USA||0|
|NCT04001413||Phase II||Durvalumab Durvalumab + MEDI0457||Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients||Withdrawn||USA||0|
|NCT03439085||Phase II||Durvalumab + MEDI0457||Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers||Active, not recruiting||USA||0|